Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.681
-0.002 (-0.29%)
At close: Feb 27, 2026, 4:00 PM EST
0.660
-0.021 (-3.04%)
After-hours: Feb 27, 2026, 7:58 PM EST
Decoy Therapeutics Employees
Decoy Therapeutics had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,502,379
Market Cap
4.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| GeoVax Labs | 17 |
| Genprex | 13 |
| BioRestorative Therapies | 11 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Acurx Pharmaceuticals | 4 |
| PMGC Holdings | 3 |
DCOY News
- 17 days ago - Decoy Therapeutics Joins Webull Corporate Connect Service Platform - PRNewsWire
- 23 days ago - Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - PRNewsWire
- 24 days ago - Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - PRNewsWire
- 6 weeks ago - Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PRNewsWire
- 7 weeks ago - Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewsWire